Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells

Nam, Hyunwoo; Lee, In Hee; Jason, K.; Kim, Sung Soo; Pyeon, Hee Jang; Lee, Kee Hang; Lee, Kyung-Hoon; Lee, Sun-Ho; Joo, Kyeung Min

doi:10.1007/s12015-021-10290-z

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome those limitations, recently, we demonstrated that ahNSCs derived from focal cortical dysplasia (FCD) type IIIa have cellular properties like neural stem/precursor cells, including a self-renewing and neural-differentiation potency [14][15][16][17][18]. In this study, we analyzed the therapeutic effects of ahNSCs isolated from temporal lobes of focal cortical dysplasia type IIIa for SCI and to elucidate their treatment mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Significant Therapeutic Effects of Adult Human Neural Stem Cells for Spinal Cord Injury Are Mediated by Monocyte Chemoattractant Protein-1 (MCP-1)

Kim

Won

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

The limited capability of regeneration in the human central nervous system leads to severe and permanent disabilities following spinal cord injury (SCI) while patients suffer from no viable treatment option. Adult human neural stem cells (ahNSCs) are unique cells derived from the adult human brain, which have the essential characteristics of NSCs. The objective of this study was to characterize the therapeutic effects of ahNSCs isolated from the temporal lobes of focal cortical dysplasia type IIIa for SCI and to elucidate their treatment mechanisms. Results showed that the recovery of motor functions was significantly improved in groups transplanted with ahNSCs, where, in damaged regions of spinal cords, the numbers of both spread and regenerated nerve fibers were observed to be higher than the vehicle group. In addition, the distance between neuronal nuclei in damaged spinal cord tissue was significantly closer in treatment groups than the vehicle group. Based on an immunohistochemistry analysis, those neuroprotective effects of ahNSCs in SCI were found to be mediated by inhibiting apoptosis of spinal cord neurons. Moreover, the analysis of the conditioned medium (CM) of ahNSCs revealed that such neuroprotective effects were mediated by paracrine effects with various types of cytokines released from ahNSCs, where monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) was identified as a key paracrine mediator. These results of ahNSCs could be utilized further in the preclinical and clinical development of effective and safe cell therapeutics for SCI, with no available therapeutic options at present.

show abstract